कृपया अन्य खोज का प्रयास करें
Kiadis Pharma N.V., a biopharmaceutical company, develops NK-cell-based medicines for the treatment of life-threatening diseases in the Netherlands. Its lead product candidate is K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol, as well as for the treatment of liquid and solid tumors and infectious diseases; and K-NK003 that is in Phase II clinical study for the treatment of patients with acute myeloid leukemia relapse/refractory. The company is also developing K-NK-ID101, which is in Phase I/II a clinical trial for the treatment of COVID-19 infection; K-NK00X, which is in preclinical stage with K-NK-cell therapies for the treatment of hematologic and solid cancers; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for a range of other cancers and infectious diseases. It has a collaboration agreement with Sanofi. The company was founded in 1997 and is based in Amsterdam, Netherlands. Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है